View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Maxime Stranart
  • Maxime Stranart

Colruyt/FY guidance reiterated despite weaker 1H25-26/BUY

We reiterate our BUY rating on Colruyt but lower our target price from €44 to €38 following Colruyt's 1H25/26F results, which came in below expectations at the operating profit level. While we note management's confident tone during its conference call, we reduce our EBIT forecast by 3.6% for FY25/26F, implying that we now sit roughly 2% below company-guidance. We expect Sunday openings as of January 2026, as well as a strong price position in Belgium to benefit top-line growth over the next eig...

David Vagman ... (+3)
  • David Vagman
  • CFA
  • Maxime Stranart

UCB/Bimzelx continues its exceptional launch/BUY

We reiterate our BUY rating and raise our target price from €257 to €310. UCB finished the year strongly, after upgrading its guidance for a second time in FY25. This upgraded guidance was mainly driven by an exceptional performance for Bimzelx, the group's key growth engine and which continues to surprise to the upside. This gives us comfort into our peak sales of €8.5bn for Bimzelx by 2032F, especially as the performance of Bimzelx in Hidradenitis Suppurativa remains strong. Alongside Bimzelx,...

Christophe-Raphaël Ganet
  • Christophe-Raphaël Ganet
Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch